POZ - Treatment News : Herpes Drug Fights HIV Too

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » November 2007

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


email print

November 13, 2007

Herpes Drug Fights HIV Too

The anti-herpes drug Valtrex (valacyclovir) has been found to lower HIV viral load in the blood and genital secretions of men with underlying herpes simplex vius-2 (HSV-2) infection, according to a report on a study from AIDSmap. The study confirms earlier research and further suggests that herpes treatment, in the absence of HIV therapy, may have health benefits and help prevent ongoing transmission of HIV.

Richard Zuckerman, MD, MPH, of the section of infectious disease and international health at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, and his colleagues studied valacyclovir treatment in 20 men infected with both HIV and HSV-2 in Lima, Peru. The men were randomized to receive either 500mg of valacyclovir twice a day or a placebo for eight weeks. Then after a two-week pause, the dosing groups were switched so that those who’d received placebo now received valacyclovir and those who’d received valacyclovir now received placebo for an additional eight weeks.

Treatment with valcyclovir was associated with a 31 percent decrease in HIV viral load from rectal samples compared with placebo, and a 53 percent decrease in HIV in the blood. The study’s authors conclude that suppressing HSV-2 production in people coinfected with HIV results in significant reductions in both HSV-2 and HIV.


Scroll down to comment on this story.

email print

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

  comments 1 - 10 (of 10 total)    

David Evans, New York, AIDSmeds.com, 2007-11-20 12:41:19
Valacyclovir should be sold as Valtrex in most countries.

Mr T. R. Toa, Wellington, New Zealand., 2007-11-19 20:36:53
Wow that is hope for people like me and I hope that it will be avaiable to people in New Zealand suffering from the HIV strand.

mandi henshaw eyambe, , 2007-11-19 16:34:23
is there a commercial name for valacyclovir in Africa?

mandi henshaw eyambe, , 2007-11-19 16:30:17
this is one of the greatest news i have gather today to help our patients mostly in the developing countries with poverty. May god be praised

jerry, Burbank WA, 2007-11-16 20:05:25
I've use Acyclovir for 15 years or so for Herpes. 1. is it the same as your Valacyclovier? 2. I haven't had a Herpes breakout in 10 years or more. 3. Could this drug be made into a enoculation against either? just wondering, jerry

Tame in SF, San Francisco, 2007-11-15 17:42:14
Valacyclovir is converted to acyclovir in the body. I have been taking twice-daily doses of acyclovir since the early 90s after studies showed that poz people who took daily acyclovir were living longer. So, this article is not reporting any news beyond raising the question of why Dr. Richard Zuckerman spending precious resources this way?

David Evans, AIDSmeds.com - New York, NY, 2007-11-15 15:08:46
Dear Cliff and Will - Acyclovir was looked at early in the epidemic, but wasn't consistently found in studies to greatly impact HIV. You're right that the theory of controlling herpes being good for HIV control too is not a new one. Louis - please look at our drug page on Reyataz for many of the drugs it interacts with.

Cliff, London, 2007-11-14 17:25:03
This doesn't seem like "news" to me. When I was first infected, I remember reading about Valtrax providing an indirect benefit to HIV patients by reducing immune activation as a result of a chronic herpes infection.

Louis Bernard, New Orleans, 2007-11-14 14:33:33
I am crrently taking Reyataz, but I was not made aware of all the drigs that it has problems with. Where can I download all this info?

Will Rath, S. California, 2007-11-14 13:02:41
regarding the improved V.L.results with valcyclovir, is the same, or similar result achievable with acyclovir?

comments 1 - 10 (of 10 total)    


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar
Starting Treatment
Quilt in the Capital
POZ Army


    adoniz89
    san dimas
    California


    newlife202
    JOLIET
    Illinois


    MascVersWPB
    Lake Worth
    Florida


    jdog46948
    Detroit
    Michigan
Click here to join POZ Personals!
Talk to Us
Poll
Do you support rapid in-home HIV testing?
Yes
No

Survey
Health 2.0

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.